Theravance Biopharma

NCT00887406

Study of GSK961081 in Healthy Volunteer Subjects

NCT00550225

Succinate Salt Version of GSK961081 for Healthy Volunteers

NCT00687700

A Study to Investigate the Pharmacology of a Dual Pharmacophore in Healthy Volunteers

NCT01467726

Safety, Pharmacokinetics and Pharmacodynamics of Velusetrag in Healthy Elderly Subjects

NCT01568411

A Fixed-Sequence, Two-Period, Open-Label Drug-Drug Interaction Study to Assess the Effect of an Inhibitor of Cytochrome P450 Isoenzyme 3A4 and Permeability Glycoprotein 1 on the Pharmacokinetics of TD-1211

NCT01655771

TD-1211 Single-Dose Study in Elderly and Young Healthy Subjects

NCT01644240

A Phase 1, Multiple Intravenous Dose Study to Examine Safety, Tolerability, and PK of Intravenous TD-8954, a 5-HT4 Receptor Agonist, in Healthy Subjects

NCT01702194

TD-1211 IV/Oral Mass Balance Study

NCT01791049

TD-1607 SAD Study in Healthy Subjects

NCT01924143

TD-9855 Mass Balance Study

NCT01949103

TD-1607 MAD Study in Healthy Subjects

NCT02022306

TD-6450 SAD and MAD in Healthy Subjects

NCT02116543

TD-6450 MAD Study in HCV Infected Subjects

NCT02772159

TD-4208 Absorption, Distribution, Metabolism and Excretion (ADME) Study in Healthy Male Subjects

NCT02639078

Single Ascending Dose Study of TD-0714 in Healthy Subjects

NCT02581592

Pharmacokinetics of TD-4208 in Patients With Moderate Hepatic Impairment

NCT02657122

SAD and MAD Study to Evaluate Safety, Tolerability, and Pharmacokinetics (PK) of TD-1473 in Healthy Subjects

NCT02578082

Pharmacokinetics of TD-4208 in Patients With Severe Renal Impairment

NCT02663089

A Phase 1 (Ph1), Single Dose (SD), GSK961081 Absorption, Distribution, Metabolism, and Excretion (ADME) Study in Healthy Subjects

NCT02709928

Multiple Ascending Dose Study of TD-0714 in Healthy and Elderly Subjects

NCT02753855

Pharmacokinetics of Telavancin in Normal and Obese Subjects

NCT02820311

Thorough QT (TQT) Study of TD-4208 in Healthy Subjects

NCT02903095

Single Ascending Dose Study of TD-1439 in Healthy Subjects

NCT02818686

TD-1473 for Active Ulcerative Colitis (UC)

NCT02954263

Multiple Ascending Dose Study of TD-1439 in Healthy Adult and Elderly Subjects

NCT03103412

TD-3504 SAD in Healthy Subjects and Subjects With Ulcerative Colitis (UC)

NCT03408470

TD-1473 Absorption, Distribution, Metabolism and Excretion (ADME) Study in Healthy Male Subjects

NCT03432793

Drug-Drug Interaction (DDI) Study for TD-9855

NCT03555617

Food-effect, Drug-Drug Interaction (DDI), and Formulation Bridging Study

NCT03652038

Single and Multiple Ascending Dose Study of TD-8236 by Inhalation

NCT03750565

Multiple Dose Ethnobridging PK Study in Healthy Subjects

NCT04044339

Single and Multiple Ascending Dose, First-in- Human Study in Healthy Subjects

NCT04200573

Effect of Hepatic Impairment on the Pharmacokinetics of a Single Dose of TD-9855

NCT04350736

First in Human SAD and MAD Study of Inhaled TD-0903, a Potential Treatment for ALI Associated With COVID-19

NCT04589260

TD-1058 First-In-Human Study in Healthy Subjects and Subjects With Idiopathic Pulmonary Fibrosis

NCT04587713

Single Dose Bioavailability and Ethnobridging PK Study in Healthy Subjects

NCT04688632

Thorough QT Study to Evaluate Ampreloxetine in Healthy Subjects

NCT05091723

TD-0903 Pharmacokinetics Study in Healthy Participants With Supplemental Oxygenation